ArticlemedRxiv : the preprint server for health sciences2026
Statin Eligibility Disparities with Transition from the Pooled Cohort Equations to the AHA PREVENT.
Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Background: The 2023 AHA PREVENT (Predicting Risk of Cardiovascular Disease Events) equations were expected to replace the 2013 ACC/AHA Pooled Cohort Equations (PCE) for estimating atherosclerotic cardiovascular disease (ASCVD) risk. The real-world implications of this transition on statin eligibility and disparity are unknown. Objectives: To evaluate how transitioning from PCE to AHA PREVENT alters statin eligibility across risk thresholds and racial and ethnic subgroups. Design Setting and Participants: Retrospective cohort analyses of adults aged 40-75 years without diabetes, LDL-C ≥190 mg/dL, or prior statin use from Sutter Health (2010-2024) and NHANES (2011-2020). Ten-year ASCVD risk was estimated using both equations. Weighted analyses were applied to NHANES data. Main Outcomes and Measures: Statin eligibility at PREVENT-ASCVD thresholds (3%, 4%, 5%, 6%, 7.5%) compared with PCE ≥7.5%, and the proportion of individuals reclassified below PREVENT-ASCVD thresholds. Results: Among 229,839 Sutter Health patients (mean age 53.7 years; 53.8% women), 22.3% had PCE risk ≥7.5%. Among individuals above PREVENT-ASCVD 5% threshold level (18.0% in the cohort) 94.7% also met PCE criteria. However, 6.3% (11,866) would lose eligibility, disproportionately affecting non-Hispanic Black adults (18.7%) compared with non-Hispanic Asian adults (3.3%) among individuals who were below PREVENT-ASCVD 5% threshold. In NHANES (n=3,226; representing 32.7 million adults), 9.4% overall and 21.7% of non-Hispanic Black adults with PCE ≥7.5% lost eligibility at PREVENT-ASCVD 5% threshold level. Conclusions: Transitioning from PCE to PREVENT recalibrates statin eligibility and may disproportionately affect non-Hispanic Black adults. Disparity-focused monitoring is essential for clinical implementation of this new model.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.